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Preimplantation genetic diagnosis (PGD) is now well established and provided in many European
countries. However, regulations, professional standards and accreditation requirements can differ notably.
Furthermore, no comprehensive independent data exist either about practice and provision in Europe or
about the quality assurance practices and procedures designed to optimize the quality of the results.
Consequently, a study was launched to obtain knowledge, currently lacking, of the provision and quality
assurance of PGD services and cross-border activities in Europe. An online questionnaire was developed
and sent to PGD providers, and expert opinions were obtained through interviews with professionals in
specific countries. Information was gathered from 53 centres offering PGD in 17 European countries. There
is a diverse array of tests available, with a trend for custom-made services. Although half of the centres
have a designated quality manager, just 33% have achieved or are preparing for accreditation or
certification. About 66% of the centres responded that they did not participate in external quality
assessment, a problem exacerbated by the lack of existing PGD-specific schemes. Approximately 19% of
the centres do not keep data on accuracy and 9% do not even follow up until birth. PGD is an expanding
activity with an increasing international flow that accounts for approximately one-third of the activity
reported. The survey highlights a significant need for improvement in quality assurance in PGD centres. On
the positive side, important improvements in the quality management of these services are expected with
the European Tissue Directive entering into force.
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Introduction
Preimplantation genetic diagnosis (PGD) involves the
genetic testing of embryos generated by in vitro fertilization
(IVF), principally to assist couples at high risk of transmitting
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a severe genetic disease to have unaffected children
without needing to resort to prenatal diagnosis and
potential termination.1 Since its initial application for
sexing in the early 1990s,2 PGD has expanded in scope to
include, for example, HLA typing for tissue donation or
non-medical sex selection.
Although PGD is now a well-established treatment
provided in many European countries, no current, com-
prehensive independent data exist about the practice and
provision of PGD in Europe. As a result of differences in
regulation, legislation and technical infrastructure between
European countries,3 patients and/or samples are often
referred internationally, but data are lacking on the scale
and nature of international flow as well as on access to
PGD across Europe. The need for thorough quality
assurance in assisted reproduction has been underlined
for clinics, laboratories and treatment procedures, with the
suggestion that European providers should have a formal
quality system.3,4 Despite this call and the recent publication
of voluntary best practice guidelines for PGD,5,6 little
information exists on current practice. In response to these
concerns, the European Commission’s Joint Research
Centre launched a study in collaboration with EuroGentest
and ESHRE (involving mainly the ESHRE PGD Consortium),
in which a survey was conducted to assess the provision
of PGD services in Europe, the access by patients and the
current state of quality assurance.
Materials and methods
A dynamic online questionnaire, using a dependency
approach in which the questions asked change according
to the answers given, was developed, containing distinct
sections for the three classes of PGD service providers: IVF
clinics (which receive patients and perform the medical
procedures of IVF), IVF laboratories (which perform the
laboratory procedures of IVF, including fertilization and
culture) and PGD laboratories (which perform the genetic
analyses) (http://www.jrc.es/publications/pub.cfm?id=1531).
Preimplantation genetic screening (PGS, formerly PGD-AS),
which is performed to detect embryonic aneuploidy
with the aim of improving pregnancy rates in couples
undergoing IVF, is distinguished from PGD in Europe and
was excluded from this study wherever possible.
Given the current lack of registries or official listings
(other than the ESHRE PGD Consortium7), the distribution
list was broadened to ensure the most comprehensive
coverage possible of centres potentially performing PGD,
with the effect that the response rate appears low (for
details, see http://www.jrc.es/publications/pub.cfm?id=1531).
The contact lists were compiled using the ESHRE PGD
Consortium list, the ESHRE membership database
and some medical genetics laboratories offering PGD
previously identified by EuroGentest through their
quality assurance survey. The survey was thus distributed
to 169 known or likely PGD providers as well as to over
1500 IVF professionals.
On submission, the replies were automatically inserted
into a database to simplify analysis. The responses are
compared to other sources, where available,5,7,8 and to
expert opinions obtained through interviews conducted
with professionals in specific countries.
To complement the information on current practices
gathered by the survey and to obtain a more detailed
picture of the situation, expert knowledge was sought
through interviews conducted with genetic laboratories
and IVF clinics offering PGD. Finally, to obtain a full
understanding of how PGD is provided in Europe, EU
regulations that impact upon the provision of PGD as well
as regulatory frameworks in different European countries
were examined in detail (manuscript in preparation).
Results
Who provides PGD?
We received 71 responses from the 169 centres approached
(Table 1):
 53 centres provided PGD:
* 44 performed both PGD and IVF (‘IVFþ PGD’)
* 9 performed PGD only, receiving samples from an IVF
laboratory (‘PGD only’)
Two categories of PGD non-providers also replied and were
excluded from the study:
 8 centres performed IVF but offered PGD, outsourcing
the genetic analysis (‘IVFþPGD referred’);
 10 replies were received mistakenly from centres that did
not offer PGD (IVF only).
The 53 providers consisted of 141 laboratories and clinics
(53 genetics laboratories, 44 IVF clinics and 44 IVF
laboratories). They were asked ‘How close is the PGD
laboratory to the IVF clinic?’ and 68 replies were received,
as some laboratories and clinics work with multiple
partners. In 58/68 cases, both partners were in the same
institution or city. In eight cases (five IVFþPGD laboratories,
three PGD only), the IVF clinics were in the ‘same
country’ and in two cases (both PGD only), in different
countries.
The greatest numbers of providers responded from Spain,
Greece, Belgium, the Czech Republic and the United
Kingdom, respectively. Overall, the centres were equally
distributed between private (41%) and public (46%)
settings (Table 1), although ‘PGD only’ centres were more
likely to be in the private sector (78%). Most private centres
were located in the Czech Republic, Greece, Spain and
Turkey.
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Independent data are scarce on the scale of PGD use in
Europe and consequently the approximate number of PGD
cycles performed in 2005 was an important aspect of this
survey. The largest centres, declaring over 100 cycles, were
in Belgium, Cyprus, the Czech Republic, France, Greece,
Spain and Turkey. With the exception of Cyprus (from
which only one centre replied), this correlates with those
countries with three or more centres (Table 1).
Forty-nine of the 53 PGD providers (92%) gave data on
the number of cycles they performed in 2005, selecting
from possible answers of ‘1–10, 11–20, 21–50, 51–100
and 4100’. In this way, they declared a total of 2410±450
PGD cycles, significantly above the estimate of approximately
1000 cycles annually worldwide.3 A potential cause of
overestimation in this figure is that although the survey
was designed specifically to exclude PGS, some laboratories
may nonetheless have included PGS in their self-declared
data (this is probably the case for some German and Dutch
laboratories; personal communication). An underestimate
is more likely, as (a) the 12 large laboratories responding
‘4100 cycles’ are conservatively counted for this calculation
as only 100, (b) four centres did not provide numbers
and (c) it is possible that not every centre performing PGD
in Europe in 2005 was identified.
Thirty-nine of the 53 (74%) providers voluntarily con-
tributed to the European Society of Human Reproduction
and Embryology (ESHRE) PGD consortium and reported
1182 PGD (plus 1722 PGS and 80 social-sexing) cycles in
2004, the last data compilation available7 at the moment
of writing; thus, the data are of similar magnitude.
In a recent survey of IVF clinic directors in the United
States, 137/186 IVF clinics reported that they have
provided PGD services to patients, resulting in a total of
approximately 1200 PGD cycles (plus approximately 2200
PGS) in 2005.8 A major difference in organization is
revealed by the fact that in the United States only 14%
(n¼19) of the IVF–PGD clinics perform some PGD genetic
analysis ‘in-house’, whereas the majority send biopsy
samples to external laboratories.
What kinds of tests are available?
Testing for chromosomal anomalies is the most widespread
service, offered by 48 laboratories in 17 countries
(Figure 1a). Most of these laboratories also perform PGS,
which requires similar FISH technology as well as sex
selection for X-linked genetic disorders. Technical and
clinical details of cytogenetic testing are thoroughly
covered elsewhere and were not requested.7
Molecular genetic testing for monogenic disorders is
offered by 37 laboratories from 15 countries; 34/37 also
perform chromosomal testing, whereas 3 perform only
monogenic PGD analysis. Thirty-five centres offered mutation
detection in probands/parents, that is, performed genetic
diagnosis outside PGD.
Similarly, centres were asked if they confirmed the
identification of mutations and/or familial translocations
when families were referred for PGD, which is important
to guarantee the correct identification and assignment
of the anomaly. Mutations were confirmed in the majority
of cases: 34/49 responding laboratories confirmed ‘in all
cases’, 11/49 in ‘450%’ and only 3 in ‘o 50%’. One
laboratory ‘always trusts an external report’ and 4 did not
respond.
Table 1 Distribution of laboratories and PGD cycles per country
PGD cycles
2005
All centers PGD only IVF+PGD
IVF+PGD
referred
Private Public Total Private Public Total Private Public Total Private Public Total
Belgium B370 0 5 6 5 6
Czech Republic B240 3 1 6 1 0 1 2 1 5
France B300 0 3 3 0 3 3
Germany B110 1 2 4 1 2 3 1
Greece B260 5 2 7 2 1 3 3 0 3 0 1 1
Netherlands B150 0 3 3 0 3 3
Spain B530 9 1 10 3 0 3 4 1 5 2 0 2
Turkey B300 3 1 4 1 0 1 2 0 2 0 1 1
United Kingdom B180 1 4 6 1 3 5 0 1 1
Other B420 3 6 12 0 1 1 1 5 9 2 0 2
Total numbers 2410±450a 25 (41%) 28 (46%) 61b 7 (78%) 2 (22%) 9 14 (32%) 23 (52%) 44b 4 (50%) 3 (38%) 8b
The countries that participated in the survey are listed according to their activity and public/private status. PGD only: laboratory performing only PGD,
receiving samples from an IVF laboratory; IVF+PGD: centre offering both laboratory services; IVF+PGD referred: IVF laboratories which act as gateways,
collaborating with external PGD laboratories to offer PGD to their patients. Ten responding centres provided IVF only and were excluded from the
study.
Bold text indicates the ‘Top 7’ countries which performed over 150 cycles in 2005. The eight countries with less than three PGD providers are grouped
in ‘other’.
aForty-nine out of fifty-three PGD providers gave data on the number of cycles, which were calculated from ranges (possible answers ‘1–10, 11–20,
21–50, 51–100 and 4100’); see text for details.
bFour IVF+PGD centres had mixed public/private affiliations, and four (three IVF+PGD and one IVF+PGD referred) did not reply.
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The ‘top 10’ monogenic diseases (Figure 1b) are almost
identical to those reported in 2004.7 Most are potentially
severe and of early onset and represent common indications
for prenatal diagnosis. On average, each laboratory
offered 5.1 of the top 10 tests, increasing to 5.6 in those
countries reporting over 150 cycles in 2005 (the ‘top 7’, see
Table 1) with Turkey, France and Belgium having the
highest counts (9.0, 8.0 and 7.7, respectively). Each of the
top 10 tests was offered by an average of 1.6 laboratories per
country, indicating that overall there is little redundancy
in the provision of services; however, in the top 7
countries, this increases to 2.3 laboratories per test, with
Spain and Belgium having the highest overlaps with 4.4
and 2.4 laboratories performing each test, respectively.
Approximately 50 distinct monogenic disorders were
cited as indications for PGD (Table 2), with some
laboratories responding with ‘more than 50 indications’
or a ‘custom-made analysis of any disease of known genetic
cause’. Thirty-five of these disorders appear in the list of 57
conditions reported in 2004.7
Overall, these data reveal a clear tendency for laboratories
to offer custom-made tests with little specialization in
or coordinated repartition of, particular diseases within
countries.
The different perception and application of PGD compared
with prenatal diagnosis becomes apparent with the wide-
spread availability of testing for adult-onset disorders in 24
of the 37 laboratories doing monogenic PGD. Conditions
notably included Huntington (HD) and Charcot-Marie-
Tooth (CMT) disease, offered by 17 and 9 laboratories,
respectively, plus many familial cancer predispositions.
Prenatal testing for HD is available in genetics centres
worldwide,9 although it continues to incite debate because
of its late onset and because of issues of consent and
privacy – notably, prenatal diagnosis can reveal the status
of an untested parent, an issue that can be avoided with
PGD. Prenatal diagnosis for CMT is uncommon owing to
its relatively benign course and clinical heterogeneity.10
Similarly, prenatal diagnosis is uncommon for inherited
Table 2 Indications for monogenic PGD reported in the
survey
Autosomal dominant
Autosomal
recessive X-linked
Achondroplasia b-Thalassemia Duchenne/
Becker MD
Angelman/UBE3A Cystic fibrosis Fragile X
BRCA1 and BRCA2 Epidermolysis
bullosa
Hemophilia A, B
‘Cancer predisposition’a Diastrophic
dysplasia
Incontinentia
pigmenti
Charcot-Marie-Tooth
disease
Kell
isoimmunization
Lesch–Nyhan
syndrome
Crouzon syndrome Krabbe disease Leukodystrophy,
metachromatic
Ehlers–Danlos syndrome Lowe syndrome
Familial amyloidosis Tyrosine
hydroxylase
deficiency
Hypochondroplasia
Huntington’s disease San Filippo
(MPS III)
Wiscott–Aldrich
syndrome
Von Hippel–Landau
Marfan syndrome Sickle-cell
disease
NARP (mtDNA)
Multiple endocrine
neoplasia, 2
Spinal muscular
atrophy
Leigh’s syndrome
Myotonic dystrophy
type 1
Tay–Sachs
disease
Noonan syndrome
Neurofibromatosis
1 and 2
Polycystic kidney
disease
Pancreatitis, hereditary
Polycystic kidney disease
Polyposis coli (APC)a
Retinoblastoma
Spinocerebellar
atrophy 1, 2, 3, 7a
Tuberous sclerosis 1, 2
Approximately 50 distinct pathologies/indications for which PGD
centres offered tests in 2005; in addition, some centres replied ‘more
than 50 indications’ or ‘custom-made analysis of any disease of known
genetic cause’.
aOnset usually in adult life.
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CF
DMD
SMA
F8/F9
B-THAL
FRAXA
HD
DM1
SCD
CMT
percent of labs
PGD labs
Chromosomal anomalies 48 (91%)
Sex selection for X-linked disorders 45 (85%)
Social sex selection 1 (2%)
PGS§ 37 (70%)
Monogenic diseases 37 (70%)
Adult-onset monogenic diseases 24 (45%)
HLA matching 14 (26%)
Screen probands before PGD 35 (66%)
Figure 1 (a) PGD services available in the 53 PGD laboratories. }
PGS cycles were excluded from the presented data wherever possible
(see text). (b) Availability of testing for 10 common monogenic
diseases. The 10 most common indications for monogenic disease
PGD in 2005, in the 37 laboratories providing monogenic PGD.
Legend: CF, cystic fibrosis; DMD, Duchenne/Becker muscular dystro-
phy; SMA, spinal muscular atrophy; F8/F9, haemophilia A/B; B-THAL,
b-thalassemia; FRAXA, Fragile X syndrome; HD, Huntington disease;
DM1, Steinert myotonic dystrophy; SCD, sickle-cell disease; CMT,
Charcot-Marie-Tooth disease.
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predispositions to breast, ovarian or bowel cancers, which
are not only typically adult-onset but also have incomplete
penetrance; PGD offers an alternative that may reduce the
ethical questions but nonetheless remains controversial.11,12
Such testing was authorized in the United Kingdom in
2006, subject to licensing.13
The arrival of PGD has also led to the emergence of
certain non-diagnostic tests that were almost universally
considered as unacceptable in the context of prenatal
diagnosis. Embryonic HLA typing, to select HLA-identical
donors for siblings with a severe existing disease, represents
such a non-diagnostic application of PGD; medical, ethical
and legal aspects of preimplantation HLA typing have
been discussed recently.14 – 16 Typing was provided by 14
laboratories (26%), either simultaneously with PGD for a
monogenic disorder treatable with bone marrow transplant
or in the absence of a concomitant genetic disorder, for
example, in case of acquired haematological disease
(performed by 12/14 and 11/14 laboratories, respectively).
In the United States, 24% of laboratories perform pre-
implantation HLA testing but only 6% do so in the absence
of a concomitant inherited disorder.8
Non-medical (social) sex selection is a controversial
subject in Europe and is prohibited or actively discouraged
in some but not all European countries,17 and only one
laboratory responded that it performed social sex selection.
This is in marked contrast to the United States, where such
testing is considered more acceptable and where 42% of
PGD clinics offer non-medical sex selection.8
How is the quality of PGD assured?
Assuring patient safety through the quality of results is
mission-critical to medical laboratories. Accreditation,
according to an internationally recognized standard such
as ISO 15189, is the single most effective route to
comprehensive quality assurance, attesting to both tech-
nical competence and compliance with quality standards.
Accreditation is a formal recognition of a laboratory’s
competence to perform a test. Certification, which attests
only compliance, is a less discerning alternative. Licensing
is an official or legal permission to perform testing that is
required in some countries.
Quality management Despite this and the call for
European PGD providers to be certified or accredited,3,4
the uptake of formal systems of quality management or of
their different elements remains low (Table 3). Only 77/141
centres (55%) have a designated quality manager, an
essential early step in implementing a quality system,
and just 46/141 (33%) have achieved or are preparing for
accreditation or certification. Some countries additionally
maintain a licensing and inspection system that may fulfil
certain aspects of accreditation standards; only 11% of all
laboratories and clinics (15/141) were licensed.
Uptake of accreditation is significantly stronger in the
private sector: 11/15 accredited laboratories and clinics
(73%) and 8/16 (50%) centres working towards accreditation
or certification are private. Similarly, larger centres
are more likely to adopt a formal quality system: 7/22
(32%) centres that performed over 50 cycles are accredited
and 16/22 (73%) have obtained or are preparing
for accreditation/certification, compared with only 4/27
(15%) and 10/27 (37%), respectively, of smaller
centres. Appropriately, given the different priorities of
laboratory testing and patient care, IVF laboratories
prefer accreditation to certification, whereas IVF clinics
prefer the inverse; genetics laboratories do not follow this
choice but opt at similar frequencies for certification or
accreditation.
External quality assessment Although accreditation
standards require quality control procedures for monitoring
the validity of tests, including objective assessment of
laboratory performance by external quality assessment
(EQA), there is at present no EQA scheme available
specifically for PGD. ESHRE recommended that a voluntary
EQA scheme be implemented to ensure that related
technical aspects, interpretation and reporting of the
results are well assessed.5 Thirty-five of 53 laboratories,
and even 4 of the 7 accredited genetics laboratories,
responded that they did not participate in EQA, although
it was unclear if this concerned EQA in general or
specifically for PGD. When asked to rate the importance
of EQA, 48/49 laboratories responded with ‘very important’
or ‘important’. A single laboratory replied that EQA was
‘irrelevant’.
Table 3 Quality management systems
All IVF clinics (n¼44) IVF laboratories (n¼44) Genetics laboratories (n¼ 53)
Quality manager 55% 52% (23) 70% (31) 43% (23)
Accreditation 17% 7% (3) 20% (9) 23% (12)
Certification 17% 27% (12) 9% (4) 15% (8)
Accreditation and/or certificationa 33% 34% (15) 30% (13) 34% (18)
Providers were asked to indicate if they had a designated quality manager, and if accreditation and/or certification had been obtained or was underway
(the latter values are combined under accreditation, certification and accreditation and/or certification). The number of answers in each category
appears in parentheses.
aSome centres replied positively to both accreditation and certification.
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Qualifications The presence of directors with a PhD
degree has been previously identified as one of the major
positive quality indicators in molecular genetics labora-
tories,18 and the OECD recommends that the minimum
qualification to direct a molecular genetics laboratory be
an MD, PhD or equivalent.19.Current PGD guidelines make
no recommendations on this subject.5,6 The majority of
genetics and IVF laboratories were directed principally by
PhDs or MDs (Table 4), whereas clinics are logically
directed principally by MDs. Eight IVF laboratories (22%)
and one genetics laboratory were directed by people with
neither PhD nor MD degrees but who had only Masters or
similar graduate degrees. Most centres had formal instructions
documenting the training of staff (41/53).
Technical aspects A series of technical questions in the
survey allowed the identification of common practices in
PGD laboratories (Table 5), which were generally in close
agreement with the ESHRE guidelines and similar to
common practice in the United States.5,8 The consensus
approach was as follows:
 1 or 2 blastomeres are analysed;
 blastomeres are biopsied on day 3, from the 5 or 6 cell
stage onwards;
 biopsy is performed by a biologist/embryologist, either
alone or with a technician;
 PGD embryos are transferred 1–2 days after biopsy.
Notable exceptions from consensus practice included the
analysis of polar bodies in Austria, Germany and Switzerland,
in response to the prohibition of direct embryo
testing. Several centres in Estonia, Greece and Turkey only
biopsy blastomeres from the seven-cell stage onwards; it is
generally true that there is only a very small chance of
successful implantation of embryos that have only five or
six cells at day 3.
Two-thirds of laboratories performing monogenic PGD
(24/36) perform both direct and indirect mutation analysis,
improving the reliability of testing by eliminating the risk
of errors due to allele drop-out (testing only one of the two
alleles owing to a PCR artefact), but 10 (28%) reported that
they only perform direct analysis. ESHRE guidelines clearly
call for both direct and indirect analysis.5
The existence and use of strictly separated working zones
within the laboratory is of prime importance to avoid
contamination in PCR-based testing, particularly in the
context of PGD by single-cell analysis, and are recommended
by the ESHRE guidelines. Of the 37 laboratories performing
monogenic PGD, 20 (54%) had dedicated pre-pre-, pre-
and post-PCR rooms; a further 12 (32%) had either
pre- or post-PCR rooms but 5 had no separated facilities.
Positive and negative controls for proving reliability
Table 4 Qualifications of directors
IVF clinics
(37)
IVF laboratories
(37)
Genetics laboratories
(44)
PhD 8% (3) 65% (24) 57% (25)
MD/
PhD
32% (12) 8% (3) 20% (9)
MD 59% (22) 5% (2) 20% (9)
Other 0 22% (8) 2% (1)
The qualifications of the clinical and laboratory directors were asked;
replies were obtained from 84% of clinics and laboratories providing
PGD. The number of answers in each category appears in brackets.
‘Other’ is comprised of different types of pre-doctoral degrees.
Table 5 Technical aspects of quality assurance in labora-
tories performing PGD
All PGD
laboratories
(n¼53a)
Top 7
countries
(n¼37)
1. Cells analysed per embryo per
diagnosis?
1 blastomere 68% (36) 70% (26)
2 blastomeres 57% (30) 59% (22)
1 polar bodyb 4% (2) F
2 polar bodies 8% (4) F
(a) On which day do you usually
perform blastomere biopsy?
Day 3 100% (48) 100% (37)
(b) Which embryos do you biopsy?
From 5 cells 52% (25) 43% (16)
From 6 cells 35% (17) 41% (15)
From 7 cells 13% (6) 16% (6)
(c) Who performs the biopsy of the
embryo for PGD?
Embryologist/biologist 100% (48) 100% (37)
Laboratory technician 25% (12) 22% (8)
(d) On which day do you usually
transfer embryos following PGD?
Day 3 2% (1) F
Day 4 42% (20) 35% (13)
Day 5 52% (25) 59% (22)
Not specified 4% (2) 5% (2)
2. Do you perform positive/
negative controls?
81% (43) 84% (31)
3. Do you have dedicated rooms
for?
Monogenic
laboratories
(n¼37) (n¼28)
Pre-pre-PCR 78% (29) 82% (23)
Pre-PCR 65% (24) 75% (21)
Post-PCR 70% (26) 75% (21)
Complied replies from a series of technical questions designed to
determine current practice quality assurance. The number of answers
in each category appears in brackets. The Top 7 countries, performing
over 150 cycles in 2005, are those indicated in bold in Table 1.
aThe sum of answers is not necessarily equal to the sum of laboratories,
as multiple answers were possible and not all laboratories answered all
questions.
bPolar bodies were tested only in Austria, Germany and Switzerland.
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and identifying potential contaminations were used by
43/53 laboratories (81%), similar to the 76% of US
IVF–PGD clinics.8
Counselling, informed consent, reporting and
follow-up
PGD providers should ensure that their patients receive
suitable pre- and post-analytical genetic counselling and
that appropriate informed consent is obtained. Fifty of 53
centres (94%) responded that they do provide genetic
counselling, which may be at IVF clinics (25/50), medical
genetics services (38/50) and/or ‘from partners’ (8/50).
Similarly, 50/53 centres reported that they require
informed consent. However, the expert interviews revealed
that the relationships between IVF clinics and genetics
services may not always be completely transparent, and
concerns were raised about whether patients really did
receive adequate counselling and whose responsibility this
was.
Formal laboratory reports were issued by 50/53 (94%)
laboratories, compliant with PGDIS (2004) and ESHRE
guidelines (2005). In all laboratories, reports were signed by
a clinical scientist (24/50), an MD (7/50) or both (17/50).
Of the three centres not producing formal reports, two
were small providers (1–10 cycles) who also kept data for
only 9–12 months, whereas the majority of the centres
kept data for 42 years. The third centre probably
performed only PGS, not PGD.
Confirmation of PGD by prenatal diagnosis, which
protects against misdiagnosis but presents a small risk to
the pregnancy, is ‘recommended’ or ‘suggested’ by 44/50
(88%) centres, slightly below the 96% of US IVF–PGD
clinics that recommend or require confirmation.
Monitoring and follow-up Monitoring the accuracy of
PGD requires follow-up at the very least to the neonatal
period and ideally on a longer term, but the survey
revealed disappointingly low levels of participation. Only
48/53 (91%) laboratories follow up during pregnancy and a
lower proportion follow up to the neonatal period (Table 6).
Fifty-two out of 53 centres (98%) keep data on success rate
but only 43/53 (81%) do so on accuracy, comparable with
the United States.8
Systematic post-natal follow-up for PGD was generally
found to be very limited; it was best in Belgium but weakest
in the Czech Republic and Greece where only 2/12 centres
followed up beyond the neonatal period. Paediatric
follow-up is limited to the larger PGD centres and the
expert interviews revealed that the best monitoring is
provided by centres that provide both IVF and genetic
services at the same location. Lack of expertise and high cost
were the main reasons reported for not providing follow-up.
These data highlight a need for more thorough and
longer term follow-up and documentation of results, to
improve knowledge of the security and accuracy of PGD
and thus to increase patient safety. The ESHRE
PGD Consortium produces a detailed annual report of
PGD activity, including some aspects of quality assurance,
from its members who contribute on a voluntary basis; 39/53
(74%) of the surveyed centres were participants. The
Consortium hopes to extend its current neonatal
follow-up and to encourage monitoring of both PGD
technology and long-term follow-up with all those centres
that have the infrastructure and financial means.
National and international flow
Although patients and/or samples are often referred
internationally, little data were previously available about
the scale and nature of international flow. According to the
survey, in 2005, over 800 patients were referred interna-
tionally, equivalent to approximately one-third of all the
cycles identified by the survey; 68% of PGD centres treated
patients from abroad and 32% received samples (Table 7).
Table 6 Duration of follow-up of patients after PGD
n¼53
During pregnancy 48 (91%)
Neonatal 41 (77%)
Short-term paediatric 22 (42%)
Long-term paediatric 11 (21%)
Providers were asked ‘Your laboratory follows upy’ and could provide
multiple answers to the above categories.
Table 7 Trans-border flow of main countries treating
patients from foreign countries in 2005
No. of
replies (PGD
centres)
Received
samples from
abroad?
Treated
patients from
abroad?
No. of
patients
from abroad
Belgium 6 1 5 127
Cyprus 1 1 1 150
Czech
Republic
6 1 4 110
France 3 2 3 10a
Germany 3 0 2 22
Greece 6 3 3 18
Netherlands 3 0 1 2
Slovakia 1 0 1 20
Spain 8 4 6 332a
Turkey 3 2 3 35
United
Kingdom
5 0 2 Fa
Otherb 8 3 5 6
Total 53 17 (32%) 36 (68%) 832
A series of questions were asked to determine the current level of
movement of patients and/or samples.
aReplies about number of patients treated annually were incomplete or
absent.
bOther: Finland, Portugal, Sweden and Switzerland.
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The main receiving countries are Spain, Cyprus, Belgium
and the Czech Republic, with a significant flow of patients
also to Greece, Germany, Turkey and Slovakia. They all
treated patients from a large number of European countries,
but also from the US, Lebanon and Israel. Austria,
France, Germany, the Netherlands and the UK appeared
to be the major referrers (although the numbers of patients
referred are not available); they each sent patients and
samples to three or more foreign countries in 2005.
Belgium and the Czech Republic were the only countries
identified that were apparently self-sufficient, referring no
patients to foreign countries.
Cross-border movement of patients has been reported
to be primarily a direct consequence of the regulatory
differences across Europe,20 and this was partly supported
by the survey: legal reasons and test availability were cited
as the main drivers for flow (Table 8).
Internationally referred patients and samples clearly
represent a large part of the total PGD activity in Europe,
which might lead to concerns with regard to medical
advice, counselling, monitoring and follow-up. A degree of
harmonization may arise through the recent EU Human
Tissue and Cells Directive, which also includes PGD
practices. The Directive aims to ensure that, in time,
patients who travel abroad for treatment will know that
they can expect minimum quality and safety standards
within any country of the EU. As mentioned above,
accreditation to a standard such as ISO 15189 must be
considered the target to ensure minimal acceptable
standards in all centres providing PGD services to European
patients.
Discussion
We have surveyed practices in 53 centres offering PGD
from 17 European countries. Approximately 2–3000 PGD
cycles were performed in 2005; the most widely available
testing was for familial chromosomal anomalies (offered by
91% of laboratories), followed by monogenic diseases and
HLA typing for donor matching.
PGD for monogenic testing was available in 37 centres
from 15 countries for an average of 2.5 laboratories per
country; however, the distribution is unequal with 28 of
the laboratories in the 7 countries performing over 150
cycles in 2005. Laboratories within a country tend not to
be organized to distribute tests between themselves but to
provide a very wide diversity of tests, including even very
rare diseases: over 50 disorders were specifically cited as
being tested and a trend towards personalized testing was
underlined by laboratories indicating that they offered
tests for ‘more than 50 indications’ or even ‘custom-made
analysis of any disease of known genetic cause’. Each of the
10 most common tests, which would be the best candidates
for rational distribution, were offered by an average of 1.6
laboratories per country. A similar lack of rationalization
has been previously observed in conventional molecular
genetic testing,21 and consequently it is unsurprising to
find it repeated for PGD, particularly as the specialization
required for PGD is predominantly in single-cell diagnostics
rather than in clinical molecular genetics (mutations
are commonly initially characterized by genetics labora-
tories before referral for PGD). The high proportion of
private laboratories active in PGD may also contribute to
the tendency to offer a full catalogue of tests.
It is apparent that PGD is not simply used as an
alternative to prenatal diagnosis, but it is perceived
differently by patients and providers. First, PGD testing of
adult-onset disorders (Huntington disease, familial predis-
positions to cancer, polycystic kidney disease, etc) appears
to be more widespread than is the case for prenatal
diagnosis. Second, testing may be requested and performed
for relatively less severe or less predictable diseases: a
quarter of the centres offer PGD for CMT disease, which is
not a common prenatal diagnosis. Third, non-diagnostic
tests are performed that are not available as prenatal
diagnosis: HLA typing to select HLA-identical donors for
existing individuals with severe disease was available in
one-quarter of laboratories and 11 laboratories even offered
this as an isolated test, without also testing for monogenic
disease. A single European service responded that they
provided non-medical sex selection by PGD, which is in
contrast to the United States where it appears to be more
acceptable and is offered by 42% of providers.8
These findings suggest that PGD and embryo selection
may be regarded as less of an ethical problem than prenatal
diagnosis (with associated termination of pregnancy); a
targeted study of the indications for testing and the
experiences of families would be of significant interest.
A very high degree of international exchange was
identified, equivalent to approximately one-third of the
cycles identified by the survey. In 2005, over 800 patients
were referred internationally for PGD, two-thirds of the
centres treated patients from abroad and one-third received
samples from abroad. Movement was principally due to
legal reasons and because of test availability, revealing a
deficiency of local access to PGD for patients in some
countries. Consequently, given the high costs involved,
Table 8 Reasons for referral from foreign countries
Number (total¼36)
Legal reasons 24
Test availability 21
Financial reasons 14
Quality/reputation 4
Waiting lists 3
Other 3
Thirty-six out of fifty-three centres received patients and/or samples
from abroad. ‘Other’ reasons included experience, success rates and
expertise on certain diseases.
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there is a risk that PGD may only be available to wealthier
couples in many situations.
Although the data reveal that almost all PGD centres
provide genetic counselling and require informed consent,
concerns were raised by some experts interviewed about
whether all couples did indeed receive adequate counselling.
It would be valuable to study the availability and quality of
genetic counselling in couples who have received or are
candidates for PGD, perhaps by a retrospective survey of
couples who have undergone PGD.
The survey provides the first independent data on
quality assurance in European PGD services. It is important
to note that the reliability of PGD in Europe is currently
high; no false-negative diagnostic errors were identified
by the ESHRE PGD Consortium in 2004, although three
misdiagnoses were identified in the latest report.7,22
Nonetheless, the survey reveals overall that the investment
in quality management by PGD centres is at present
disappointingly low, notably concerning accreditation
and participation in EQA schemes. To maintain the level
of quality, it is important that accreditation be actively
encouraged or even made mandatory by policy change, as
has been recently proposed.19 The implementation of the
EU Human Tissue and Cells Directive should also have a
positive impact on quality assurance of testing services,
including PGD, by enforcing the introduction of a broad
range of quality management elements.
The presence of laboratory directors with a PhD has been
identified as a key criterion of quality assurance, and this
was the case for 75% of PGD laboratories. It would be
valuable to extend these data to specialization and formal
training in genetics, which are called for by the OECD
Guidelines19 but which were not surveyed because of their
variable availability throughout Europe.
Although accreditation is widely recognized as the single
most effective route to comprehensive quality assurance,
particularly for medical laboratories, its uptake is very low:
only 22% of PGD laboratories are accredited or preparing
for accreditation; a small number are licensed or certified
(11 and 12%, respectively). Uptake of accreditation is
significantly lower in the public sector than in the private
sector, which may suggest a lack of support from institu-
tions for investment in diagnostic quality assurance. Only
70% of laboratories and 52% of clinics had designated
quality managers.
EQA is the most important instrument for independently
determining the precision of a test in a laboratory. The
survey highlighted an important weakness in quality
assurance for PGD: although 98% of centres regard EQA
as very important or important, no purpose-designed
EQA schemes are available. The provision of schemes for
cytogenetic and molecular PGD should be considered
high priority for quality assessment and improvement,
and a first scheme for cytogenetic PGD as well as
molecular diagnosis is currently under development as a
collaboration between UKNEQAS and the ESHRE PGD
Consortium.
The replies concerning details of quality assurance
procedures reveal a wide variation in approaches to PGD;
the modal answers indicate that in the ‘average’ laboratory,
a single blastomere is sampled by an embryologist/biologist
from a 5þ cell embryo on day 3; after testing, selected
embryos are transferred 2 days later. Molecular analysis for
monogenic disorders is performed in facilities with dedicated
pre- and/or post-PCR rooms, both by direct and indirect
mutation analysis of both samples and positive and/or
negative controls.
Some causes for concern were identified of different
degrees of severity. Five laboratories performing mono-
genic PGD had no dedicated pre- nor post-PCR rooms, and
one laboratory replied that it neither had any pre- nor post-
PCR facilities nor used positive/negative controls and yet
still performs PGD for at least eight monogenic diseases.
Despite the ESHRE guidelines stating that the use of
controls is ‘contentious’ and merely ‘acceptable’, this is
clearly standard practice and is to be encouraged. Ten
laboratories (28%) perform only direct analysis during
monogenic PGD, an approach associated with a significant
risk of error.
Only 69% of laboratories confirmed anomalies (chromo-
somal or monogenic) ‘in all cases’ before undertaking PGD,
and one laboratory ‘always believes external results’, which
leaves a risk of not testing for the correct anomaly. This
indicates that some laboratories are doing insufficient
preliminary work and this identifies an element that
should be addressed by follow-up study and quality
guidelines.
Similarly unacceptable was the attitude of one laboratory
that EQA is irrelevant; quality assurance and improvement
is fundamental to patient safety and thus should be of
primary importance in medical laboratories. The discovery
that 22% of the directors of responding IVF laboratories
had neither a PhD nor an MD degree is unexpected, but
this may be subject to the precise organization of the
laboratory management.
The combined results suggest that there is a lack of
knowledge of the value and procedures of laboratory
quality assurance. This could be addressed usefully by the
provision of specialized initial and continuous education
programmes for PGD providers. It is certain that an
increased investment in quality assurance will be required
to maintain and improve standards and thus ensure
patient safety while also increasing public and regulator
confidence in PGD providers. The ESHRE PGD Consortium
has created an accreditation task force (chaired by KS) to
investigate requirements in this area.
Finally, it is evident that systematic long-term follow-up
of all children born after PGD is necessary, with the aim of
assuring quality of service and patient safety. Such a
multicentre, international, longitudinal study should be
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considered a priority and the coordination would ideally
be assured by an existing specialized group such as the
ESHRE PGD Consortium.
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